February
Thursday 15 March 2018 photo 8/15
![Canadian diabetes guidelines asa: >> http://udd.cloudz.pw/download?file=canadian+diabetes+guidelines+asa << (Download)
Canadian diabetes guidelines asa: >> http://udd.cloudz.pw/read?file=canadian+diabetes+guidelines+asa << (Read Online)
Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. James A. It is now recommended that ASA not be routinely used for primary prevention in diabetes. ASA should not be routinely used for the primary prevention of cardiovascular disease in people with diabetes [Grade A, Level 2 (36) ].
A1C (%) Standardized, validated assay, in the absence of factors that affect the accuracy of A1C and not for suspected type 1 diabetes. 6.0 – 6.4. Prediabetes. ?6.5 . A – ASA if indicated. E Exercise/Eating – regular physical activity, healthy diet, achievement and maintenance of healthy body weight. S Smoking cessation.
of cardiovascular disease (CVD), including myocar- dial infarction (MI) and stroke, is likely something that comes up frequently at family physician appointments. Acetylsalicylic acid has substantial benefits for second- ary prevention in most cases. Based on current recom- mendations, most would also agree that the benefits.
Drugs to protect your heart: Blood pressure pills (ACE inhibitors or ARBs), cholesterol lowering pills (statins), or ASA (Aspirin). These drugs will protect your heart even if your blood pressure or cholesterol is already at target.
Chapter 22: Vascular Protection in People with Diabetes. Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada
The clinical trial evidence, as reflected in the 2011 Canadian Cardiovascular Society Guidelines on the Use of Antiplatelet Therapy in the Outpatient Setting, supports the use of ASA 75 to 162 mg daily for the secondary prevention of CAD events in those with diabetes (41) .
ASA should not be used for the primary prevention of cardiovascular disease in people with diabetes. ASA may be used for secondary prevention. ACR = albumin-creatinine ratio ASA = acetylsalicylic acid ACEi = angiotensin converting enzyme inhibitor. ARB = angiotensin receptor blocker LDL = low density lipoprotein.
Does the patient have macrovascular disease? Cardiac ischemia (silent or overt); Peripheral arterial disease; Cerebrovascular/Carotid disease. Yes No. Does the patient have microvascular disease? Retinopathy; Nephropathy (ACR ? 2.0); Neuropathy. Yes No. What is the patient's age? years. Does the patient
Frequently used healthcare provider tools and resources. Physical Activity Decision Tool 2017. Screening & Diagnosis Tool. SMBG Frequency and Pattern Tool. Reducing Vascular Risk Tool. Pharmacotherapy For Type 2 Diabetes 2016. Individualizing A1C Target. Slides and Videos. Ressources francaises. CDA CPG App.
MD follows clinical practice guidelines. 8-year follow-up composite outcome: CV death, MI, CABG, PCI, Stroke, Amputation, or PVD surgery. Gaede et al. NEJM. 2003: 348;383-393. Intensive Arm. Therapies to achieve targets in glycemia, lipids, BP and microalbuminuria. Multidisciplinary care q3mo. ASA and ACE inhibitors.](http://cdn08.dayviews.com/501/_u4/_u1/_u2/_u8/_u1/_u5/u4128153/67582_1521114574/Canadian_diabetes_guidelines_asa_http_udd_cloudz_pw_download_file_canadian_diabetes_guidelines_asa.jpg)
|
Canadian diabetes guidelines asa: >> http://udd.cloudz.pw/download?file=canadian+diabetes+guidelines+asa << (Download)
Canadian diabetes guidelines asa: >> http://udd.cloudz.pw/read?file=canadian+diabetes+guidelines+asa << (Read Online)
Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. James A. It is now recommended that ASA not be routinely used for primary prevention in diabetes. ASA should not be routinely used for the primary prevention of cardiovascular disease in people with diabetes [Grade A, Level 2 (36) ].
A1C (%) Standardized, validated assay, in the absence of factors that affect the accuracy of A1C and not for suspected type 1 diabetes. 6.0 – 6.4. Prediabetes. ?6.5 . A – ASA if indicated. E Exercise/Eating – regular physical activity, healthy diet, achievement and maintenance of healthy body weight. S Smoking cessation.
of cardiovascular disease (CVD), including myocar- dial infarction (MI) and stroke, is likely something that comes up frequently at family physician appointments. Acetylsalicylic acid has substantial benefits for second- ary prevention in most cases. Based on current recom- mendations, most would also agree that the benefits.
Drugs to protect your heart: Blood pressure pills (ACE inhibitors or ARBs), cholesterol lowering pills (statins), or ASA (Aspirin). These drugs will protect your heart even if your blood pressure or cholesterol is already at target.
Chapter 22: Vascular Protection in People with Diabetes. Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada
The clinical trial evidence, as reflected in the 2011 Canadian Cardiovascular Society Guidelines on the Use of Antiplatelet Therapy in the Outpatient Setting, supports the use of ASA 75 to 162 mg daily for the secondary prevention of CAD events in those with diabetes (41) .
ASA should not be used for the primary prevention of cardiovascular disease in people with diabetes. ASA may be used for secondary prevention. ACR = albumin-creatinine ratio ASA = acetylsalicylic acid ACEi = angiotensin converting enzyme inhibitor. ARB = angiotensin receptor blocker LDL = low density lipoprotein.
Does the patient have macrovascular disease? Cardiac ischemia (silent or overt); Peripheral arterial disease; Cerebrovascular/Carotid disease. Yes No. Does the patient have microvascular disease? Retinopathy; Nephropathy (ACR ? 2.0); Neuropathy. Yes No. What is the patient's age? years. Does the patient
Frequently used healthcare provider tools and resources. Physical Activity Decision Tool 2017. Screening & Diagnosis Tool. SMBG Frequency and Pattern Tool. Reducing Vascular Risk Tool. Pharmacotherapy For Type 2 Diabetes 2016. Individualizing A1C Target. Slides and Videos. Ressources francaises. CDA CPG App.
MD follows clinical practice guidelines. 8-year follow-up composite outcome: CV death, MI, CABG, PCI, Stroke, Amputation, or PVD surgery. Gaede et al. NEJM. 2003: 348;383-393. Intensive Arm. Therapies to achieve targets in glycemia, lipids, BP and microalbuminuria. Multidisciplinary care q3mo. ASA and ACE inhibitors.
Annons
Visa toppen
Show footer